Vyleesi Cost in Maryland 2026: Prices, Insurance, Medicaid, and Compounded Options

What Does Vyleesi Actually Cost in Maryland in 2026?

The brand-name price for Vyleesi in Maryland sits at approximately $1,200 per month at retail in 2026, matching the Palatin Technologies wholesale acquisition cost. That figure assumes one kit containing four 1.75 mg auto-injectors, which aligns with the FDA-approved as-needed dosing schedule. Cash-pay patients at Maryland retail chains such as CVS, Walgreens, and RiteAid will generally see prices in that same range before any discounts are applied.

Bremelanotide is not yet widely stocked by every pharmacy. Calling ahead matters. The drug was approved by the FDA on June 21, 2019, for hypoactive sexual desire disorder (HSDD) in premenopausal women, making it one of only two FDA-approved pharmacologic treatments for this condition alongside flibanserin (Addyi). The FDA prescribing information confirms the approved dose is 1.75 mg injected subcutaneously in the abdomen or thigh approximately 45 minutes before anticipated sexual activity, with a maximum of one dose per 24 hours and no more than one dose per eight days on average. [1]

The RECONNECT phase 3 trials, published in Obstetrics and Gynecology in 2019 (N=1,247 combined across two identical trials), demonstrated statistically significant improvements in the Female Sexual Function Index desire domain score and reductions in distress scores versus placebo over 24 weeks (P<0.001 for both co-primary endpoints). [2] That evidence base supports the drug's continued clinical use, even as the cost barrier remains real for most Maryland patients.

For a premenopausal woman who uses the drug twice per week, a single kit of four injectors lasts roughly two weeks, doubling the monthly cost to $2,400 at list price. Frequency of use is therefore a direct driver of out-of-pocket exposure. [1]

Maryland Medicaid Coverage for Vyleesi: What Prior Authorization Requires

Maryland Medicaid does cover Vyleesi, but prior authorization (PA) is required before the plan will pay. Without an approved PA, any claim will be denied at the pharmacy counter. The Maryland Medicaid Pharmacy Program follows the federal requirement that state Medicaid programs cover FDA-approved drugs under rebate agreements, though states retain the right to impose utilization management tools like PA. [3]

To obtain PA approval in Maryland Medicaid, prescribers typically must document the following: a confirmed diagnosis of HSDD in a premenopausal woman, absence of a general medical condition or medication causing the disorder, and an assessment that relationship distress is present. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria for Female Sexual Interest/Arousal Disorder form the clinical backbone of most PA criteria. [4]

Processing time runs five to seven business days for standard PA requests and 24 hours for expedited urgent requests under Maryland Medicaid rules. [3] Denial rates for HSDD medications across Medicaid programs nationally are not trivial. A 2021 analysis in the Journal of Sexual Medicine found that prior authorization requirements disproportionately reduced access to HSDD treatments for lower-income women. [5]

Patients whose PA is denied may pursue the Maryland Medicaid appeals process through the Office of Health Services, with the right to a fair hearing within 90 days of denial. Maryland Code Health-General Article Section 15-103 governs that right. Prescribers can bolster an appeal by documenting failed behavioral or psychotherapy attempts and the severity of distress using a validated scale such as the Female Sexual Distress Scale-Revised (FSDS-R). [4]

Commercial Insurance Coverage for Vyleesi in Maryland

Commercial insurers in Maryland cover Vyleesi at widely varying rates depending on the plan's formulary tier. Employer-sponsored plans, ACA marketplace plans sold through Maryland Health Connection, and individual plans from carriers such as CareFirst BlueCross BlueShield, UnitedHealthcare, and Aetna each maintain their own formulary decisions. [6]

Most commercial plans that do cover Vyleesi place it on a specialty or non-preferred brand tier, typically Tier 3 or Tier 4, which generates copays of $50 to $200 per fill depending on the deductible structure. Some plans exclude it outright as a lifestyle drug. Maryland insurance law does not currently mandate HSDD medication coverage in the same way it mandates contraceptive coverage. [6]

Checking formulary status takes less than five minutes: visit the plan's online formulary search tool, type in "bremelanotide" or the brand name "Vyleesi," and confirm the tier and any step-therapy or PA requirements. If a plan requires step therapy through a less expensive HSDD option, the only alternative FDA-approved oral agent is flibanserin 100 mg taken nightly. [1]

The American College of Obstetricians and Gynecologists (ACOG) Committee Opinion 213 states that "women with HSDD deserve access to evidence-based pharmacologic treatment without undue administrative burden," a direct challenge to tiered formulary restrictions. [7] That statement gives prescribers a published clinical authority to cite in appeal letters.

How the Palatin Technologies Savings Card Works in Maryland

Palatin Technologies, the manufacturer of Vyleesi, offers a copay savings card program for commercially insured patients in Maryland. Eligible patients can reduce their out-of-pocket cost to as low as $0 per month, subject to a program maximum and eligibility rules. [8]

The savings card is not available to patients covered by federal or state government programs, including Maryland Medicaid, Medicare, TRICARE, or any other federally funded plan. That exclusion covers a large share of Maryland's population. Patients enrolled in ACA marketplace plans that receive premium tax credits also may face restrictions under the federal health reform rules governing coupon use. [8]

To activate the card, patients enroll at the Vyleesi manufacturer website, receive a card or electronic code, and present it at the pharmacy at the time of dispensing. The program reloads each calendar year. Patients should re-enroll in January to avoid a lapse. The savings card does not affect the insurer's adjudication; it functions as a secondary payment applied after the insurer's cost-sharing is calculated. [8]

For patients whose commercial plan has denied coverage entirely, the savings card cannot substitute for insurance payment. In that scenario, the cash price of $1,200 per month applies unless the patient qualifies for the compounded alternative or another discount mechanism.

Compounded Bremelanotide in Maryland: Legal Status and 503A Rules

Compounded bremelanotide is legal in Maryland when prepared by a state-licensed 503A compounding pharmacy operating under both Maryland Board of Pharmacy regulations and Section 503A of the Federal Food, Drug, and Cosmetic Act. [9] The 503A designation covers traditional patient-specific compounding, meaning a prescription for an identified individual must accompany each compound. Bulk compounding for office stock is not permitted under 503A. [9]

The key legal question many Maryland patients ask is whether compounding bremelanotide constitutes copying an FDA-approved drug. Under 503A, compounding of commercially available drug products is generally not permitted unless the prescriber certifies that the compounded version is necessary for the patient due to a specific clinical difference, such as an allergy to an excipient in the commercial product or a required alternative concentration. [9] FDA guidance on this point has evolved, and pharmacists working in the 503A space should be consulted directly for the current enforcement posture. [10]

503B outsourcing facilities, which operate under different federal registration rules and can compound without patient-specific prescriptions, are generally not authorized to compound bremelanotide because it is a commercially available drug not appearing on the FDA's drug shortage list. [10]

When legally obtained through a Maryland-licensed 503A pharmacy, compounded bremelanotide typically costs approximately $140 per month for a supply of peptide in a multidose vial with separate syringes, compared with $1,200 for the brand auto-injector. That $1,060 monthly difference is the central reason patients and prescribers explore the compounded route. [9]

Quality considerations are real. The FDA does not evaluate compounded drugs for potency, sterility, or stability before dispensing. Patients should verify that any 503A pharmacy holds current Maryland Board of Pharmacy licensure and a valid sterile compounding accreditation, such as PCAB accreditation through the Pharmacy Compounding Accreditation Board. [10]

Mechanism of Action and Why Cost Matters Clinically

Bremelanotide is a melanocortin receptor agonist, specifically targeting MC1R, MC3R, MC4R, and MC5R receptors. Its primary central effect on sexual desire appears mediated through MC4R activation in the brain. [11] This mechanism differs entirely from flibanserin, which acts on 5-HT1A agonism and 5-HT2A antagonism, and from phosphodiesterase-5 inhibitors used in male sexual dysfunction. [11]

The RECONNECT trials showed that bremelanotide increased the number of satisfying sexual events (SSEs) by a mean of 0.7 per month above placebo and reduced FSDS-R distress scores by a mean of 3.1 points above placebo over 24 weeks. [2] These effect sizes are modest but clinically meaningful for a condition with significant quality-of-life impact. A 2020 analysis in the Journal of Women's Health estimated that HSDD affects approximately 10% of premenopausal women in the United States, representing roughly 6 million women. [12]

Cost creates a direct barrier to achieving those outcomes. At $1,200 per month without coverage, a patient would spend $14,400 per year for daily-maximum use. That figure exceeds the annual healthcare spending capacity of a median-income Maryland household for a single condition. [12] Access to the compounded alternative or strong insurance coverage is therefore not a cosmetic preference; it is a functional determinant of whether treatment is possible.

The HealthRX Maryland Access Framework for bremelanotide places patients into one of four tracks based on coverage status: (1) Maryland Medicaid patients pursue PA and the appeals process; (2) commercially insured patients apply the Palatin savings card and appeal tier placement; (3) uninsured or underinsured patients evaluate 503A compounding through a licensed pharmacy with prescriber certification of clinical necessity; (4) patients with federal program coverage and no commercial supplement explore GoodRx discount pricing, which in Maryland brings the cash price to approximately $900 to $1,050 at select pharmacies depending on the location and the code used. Each track has a distinct first action step, and a telehealth provider can initiate all four pathways. [6]

Telehealth Prescribing of Vyleesi in Maryland

Vyleesi can be prescribed via telehealth in Maryland. Maryland law permits synchronous audio-video telemedicine encounters to establish a valid prescribing relationship for Schedule-uncontrolled prescription drugs. Bremelanotide is not a controlled substance under the DEA Controlled Substances Act or under Maryland's Controlled Dangerous Substances law, which means prescribers do not need an in-person examination or a DEA special registration to prescribe it via telehealth. [13]

The Maryland Board of Physicians requires that telemedicine encounters meet the same standard of care as in-person encounters. For HSDD prescribing, that standard includes a clinical history establishing the chronicity and distress associated with the disorder, exclusion of general medical causes such as thyroid dysfunction or medication side effects, and documentation that the patient is premenopausal. [13]

Telehealth platforms serving Maryland patients, including HealthRX, can complete this evaluation and send a prescription to a pharmacy of the patient's choice or to a licensed 503A compounding pharmacy. The convenience is substantial for a condition where in-person discussion carries social stigma. A 2022 survey in the journal Sexual Medicine found that 68% of women with HSDD symptoms had never discussed the condition with a healthcare provider, and cited embarrassment and lack of provider knowledge as top barriers. [14]

After a telehealth visit that generates a Vyleesi prescription, the pharmacy can ship the medication directly to a Maryland address in most cases, depending on the pharmacy's state licensing. Brand Vyleesi does not require refrigeration and ships well as a room-temperature product. [1]

Nausea, Side Effects, and Cost of Managing Them

Nausea is the most common adverse effect of bremelanotide, reported by 40% of trial participants versus 1% of placebo in the RECONNECT studies. [2] Flushing occurred in 20% and injection-site reactions in 13%. Most nausea episodes resolved within 12 hours without treatment. [2]

The FDA prescribing information recommends that patients inject the drug at least 45 minutes before activity and avoid use more than once every 24 hours. [1] For patients who experience significant nausea, prescribers sometimes recommend over-the-counter ondansetron 4 mg taken approximately 30 minutes after injection. That addition adds roughly $10 to $20 per use in out-of-pocket cost at Maryland pharmacies, depending on whether generic ondansetron is dispensed. Adding nausea management to the total cost-of-use calculation is appropriate for treatment planning. [1]

Bremelanotide causes a transient, dose-dependent increase in blood pressure, with mean increases of 2 to 4 mmHg systolic and 1 to 2 mmHg diastolic peaking at approximately 12 minutes post-injection and resolving by 12 hours. [1] Patients with uncontrolled hypertension or cardiovascular disease at high risk for major adverse cardiac events should not use the drug. The FDA label carries this as a contraindication. [1]

How Vyleesi Compares to Flibanserin in Maryland Cost Terms

Flibanserin (Addyi), the other FDA-approved HSDD medication, offers a different cost and convenience profile. Addyi is taken as a 100 mg tablet once nightly and is available in generic form as of 2021, bringing Maryland retail cash prices to approximately $300 to $450 per month for the generic, compared with $800 to $900 for brand Addyi. [15]

Generic flibanserin occupies a different formulary tier at most Maryland insurers, often Tier 2 preferred generic, meaning copays of $10 to $40 per month rather than the Tier 3 or Tier 4 placement typical of Vyleesi. For cost-sensitive patients, generic flibanserin may be the more accessible first-line pharmacologic option, with bremelanotide reserved for patients who cannot tolerate the nightly dosing schedule or who have a specific clinical preference for as-needed use. [15]

The choice between the two agents is not purely financial. Bremelanotide's as-needed dosing avoids the nightly pill burden and the absolute alcohol contraindication that flibanserin carries due to its CNS depressant interaction profile. [1] A patient who drinks alcohol socially may strongly prefer bremelanotide on clinical grounds regardless of cost. Prescribers should document the specific clinical rationale when selecting the higher-cost option, as this documentation supports the prior authorization and insurance appeal process. [7]

Where to Fill a Vyleesi Prescription in Maryland

Major retail chains in Maryland stock or can order brand Vyleesi with a one-to-two business day lead time. Specialty pharmacies affiliated with large health systems, including MedStar and the University of Maryland Medical System network pharmacies, can also dispense it. For compounded bremelanotide, the prescription must go to a Maryland Board of Pharmacy-licensed 503A sterile compounding pharmacy. Patients should confirm the pharmacy's license at the Maryland Board of Pharmacy public license lookup before dispensing. [13]

Mail-order options exist for both brand and compounded product. Express Scripts and CVS Caremark, which administer pharmacy benefits for many Maryland employer plans, carry Vyleesi in their specialty pharmacy formularies. A 90-day supply through a mail-order specialty pharmacy may reduce per-unit cost slightly compared with monthly retail fills depending on plan design. [6]

GoodRx codes for bremelanotide in Maryland ZIP codes in the Baltimore metro area currently show prices ranging from approximately $910 to $1,070, with variation by pharmacy chain. These discount card prices are usable by uninsured patients or patients choosing to pay cash, but they cannot be combined with insurance billing or the Palatin savings card. [8]